Caspase-2 is essential for proliferation and self-renewal of nucleophosmin-mutated acute myeloid leukemia.
D. Sakthivel, A. N. Brown-Suedel, F. Keane, S. Huang, K. Mc Sherry, C. I. Charendoff, K. P. Dunne, D. J. Robichaux, B. Le, C. S. Shin, A. F. Carisey, J. M. Flanagan, L. Bouchier-Hayes
Abstract
Mutation in nucleophosmin (NPM1) causes relocalization of this normally nucleolar protein to the cytoplasm (NPM1c+). Despite NPM1 mutation being the most common driver mutation in cytogenetically normal adult acute myeloid leukemia (AML), the mechanisms of NPM1c+-induced leukemogenesis remain unclear. Caspase-2 is a pro-apoptotic protein activated by NPM1 in the nucleolus. Here, we show that caspase-2 is also activated by NPM1c+ in the cytoplasm, and DNA damage-induced apoptosis is caspase-2-dependent in NPM1c+ AML but not in NPM1wt cells. Strikingly, in NPM1c+ cells, loss of caspase-2 results in profound cell cycle arrest, differentiation, and down-regulation of stem cell pathways that regulate pluripotency including impairment in the AKT/mTORC1 and Wnt signaling pathways. In contrast, there were minimal differences in proliferation, differentiation, or the transcriptional profile of NPM1wt cells with and without caspase-2. Together, these results show that caspase-2 is essential for proliferation and self-renewal of AML cells that have mutated NPM1. This study demonstrates that caspase-2 is a major effector of NPM1c+ function and may even be a druggable target to treat NPM1c+ AML and prevent relapse.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Nucleophosmin mutations lead to abnormal, but reversible, nucleoli architecture and aggregate formation - implications for NPM1-targeting therapies in AML
Martin A. Grundy, Kellie Lucken, … Claire Seedhouse·Journal of Cell SciencePeer-reviewed·Apr 22, 2025
- Nuclear Phase Separation Drives NPM1-mutant Acute Myeloid Leukemia
Gandhar K. Datar, Elmira Khabusheva, … Joshua A. Riback·CellPeer-reviewed·Nov 4, 2025
- Novel Strategy against AML by Rescuing Loss of Phase Separation of Pathogenic NPM1c
Yuting Zhu, Weifan Xu, … Pilong Li·bioRxiv·Apr 8, 2025
- Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in NPM1-mutated AML
G. Pianigiani, A. Gagliardi, … L. Brunetti·bioRxiv·Dec 11, 2021
- The NLRP3/eIF2 axis drives cell cycle progression in acute myeloid leukemia
M. Luciano, C. Blöchl, … J. Horejs-Hoeck·bioRxiv·Jun 25, 2021
- Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin
K. Kuzelova, B. Brodska, … J. Mayer·bioRxiv·Sep 7, 2018